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A response to
A commentary on “Antipsychotic-induced parkinsonism is associated with working memory
deficits in schizophrenia-spectrum disorders”
by Salem, A. andMoustafa, A. A. (2015). Front. Behav. Neurosci. 9, 131. doi: 10.3389/fnbeh.2015.00131
We read with interest the commentary from Drs Salem and Moustafa (2015) on our paper and we
would like to take the opportunity to further discuss two issues, namely, the use of chlorpromazine
equivalents (CPZs) to control for the effects of antipsychotics and the need for longitudinal studies
examining the complex relationships between cognition and antipsychotic-induced extrapyramidal
symptoms (EPS) in schizophrenia.
Drs Salem and Moustafa suggested calculating CPZs as means to rule out confounding dosage
and variations in drugs. Although we agree with the notion put forward by the authors, especially
in the context of a study investigating the side effects of antipsychotics, we would like to reiterate
that there is yet to be a widely accepted robust antipsychotic dosage comparison system that reliably
yields consistent equivalences across drugs (Patel et al., 2013). CPZs can be obtained via one of three
calculations described by Patel et al. (2013): the mean effective dose in flexible-dose studies, the
minimum effective dose, and the consensus of experts method. These methods yield inconsistent
results particularly in the case of antipsychotics with low affinities for dopamine-D2 receptors
(Sweileh et al., 2014). In our study, out of 82 schizophrenia-spectrum patients, 24 patients were
treated with clozapine and 18 with quetiapine. In the literature, we note significant fluctuations in
CPZs for quetiapine (60–175.5mg/day) and clozapine (50–138.8mg/day), an ambiguity highlighted
when the two drugs are considered relative to one another (see Table S1 in SupplementaryMaterial).
In fact, depending on the CPZ calculationmethod, quetiapine will be consideredmore or less potent
than clozapine. Therefore, even when only one equivalence system is employed, the comparison
of antipsychotic medication dosage between studies for an individual drug is troublesome, and
interpreting between-drug differences is problematic. The limited number of studies comparing
directly atypical antipsychotics to chlorpromazine, an older typical antipsychotic, might explain
some of the variability between the CPZ calculations. Nevertheless, when examining olanzapine
equivalents, a system based on the availability of a larger set of randomized-controlled trials (RCTs)
(Leucht et al., 2014, 2015), significant discrepancies between calculation methods of over 30% can






















Bellack et al. (2004) Clozapine, risperidone 29 22 – – – – –
Bender et al. (2006) Clozapine, olanzapine 26 31 Allowed – SAS No Executive functioning
Bilder et al. (2002) Clozapine, olanzapine,
risperidone, haloperidol
14 101 Allowed Yes ESRS Yes Composite index (general executive and perceptual organization, declarative verbal
learning and memory, processing speed and attention, simple motor functioning)
Buchanan et al. (1994) Clozapine, haloperidol 10 38 Allowed – SAS Yes Visual memory
Davidson et al. (2009) Amisulpride, quetiapine,
ziprasidone, haloperidol
26 320 Allowed – SHRS – –
Gallhofer et al. (2007) Sertindole, haloperidol 12 32 Excluded – SAS No Speed and attention, executive functioning
Gurpegui et al. (2007) Olanzapine, risperidone 48 163 Allowed – – – –
Harvey et al. (2008) Clozapine, ziprasidone 12 100 – – – – –
Harvey et al. (2003) Olanzapine, risperidone 8 267 Allowed No ESRS Yes Verbal memory, vigilance
Harvey et al. (2006a) Olanzapine, ziprasidone 26 72 – – ESRS No Attention, task switching, verbal memory, executive functioning, verbal fluency
Harvey et al. (2006b) Quetiapine, risperidone 8 289 – – – – –
Honer et al. (2006) Clozapine+ risperidone or
clozapine+placebo
8 65 Allowed – ESRS – –
Jerrell and Ramirez (2008) Olanzapine, risperidone,
typical antipsychotic drugs
52 108 Allowed No – – –
Keefe et al. (2007b) Olanzapine, quetiapine,
risperidone
52 81 Allowed No SAS No Composite index (processing speed, reasoning and problem solving, verbal
memory and working memory, vigilance)
Keefe et al. (2007a) Olanzapine, quetiapine,
risperidone, ziprasidone,
perphenazine
78 128 Allowed Yes SAS Yes Composite index (processing speed, reasoning, working memory, verbal memory,
vigilance)
Krakowski et al. (2008) Clozapine, olanzapine,
haloperidol
12 100 Allowed – ESRS No Composite index (motor, executive function, verbal memory, visual memory,
visuospatial ability, visual motor tracking, attention)
Lee et al. (1999) Clozapine, Typical
antipsychotic drugs
52 52 Allowed No SAS Yes Verbal fluency, executive functioning, verbal working memory
Lee et al. (2007) Risperidone, haloperidol 8 20 – – – – –
Lindenmayer et al. (2007) Olanzapine, haloperidol 12 33 Allowed – SAS – –
Ljubin et al. (2000) Olanzapine, fluphenazine 22 18 – – – – –
McGurk et al. (2005) Clozapine, risperidone 29 35 – – – – –
Meltzer et al. (2008) Clozapine, olanzapine 26 24 Allowed – SAS – –
Mori et al. (2004) Olanzapine, perospirone,
quetiapine, risperidone
12 77 Allowed Yes – – –
Mortimer et al. (2007) Amisulpride, olanzapine 26 18 Excluded – AIMS – –
Muscatello et al. (2011) Aripiprazole+ clozapine or
placebo+ clozapine
24 31 – – – – –
Ernst Nielsen et al. (2014) Clozapine+ sertindole or
clozapine+placebo








































































































































































































































































































































































































































































































































































































































































be observed for both quetiapine (20–32.3mg/day) and cloza-
pine (30.6–40mg/day) (see Table S1 in Supplementary Mate-
rial). Other than CPZ, Daily Defined Doses (DDD) is a popular
platform developed to compare drug utilization (Danivas and
Venkatasubramanian, 2013). It is not, however, a measure of
therapeutic efficacy like CPZ (Patel et al., 2013). Finally, equiv-
alents of dopamine-D2 receptor occupancy appears as a relevant
system amongst the remaining alternatives, as it targets a key
neuropharmacological mechanism involved in the emergence of
antipsychotic-induced EPS (de Greef et al., 2011). Indeed, several
positron emission tomography studies have shown that antipsy-
chotics are more likely to produce EPS at dosages associated
with striatal D2 occupancy higher than 80% (Kapur and Seeman,
2001). However, the role of D2 receptors in the pathophysiology
of EPS (dystonia, dyskinesia, akathisia) other than parkinsonism
is less clear (Mehta et al., 2015). Moreover, antipsychotics bind
several receptors other than D2 contributing to, or preventing,
the emergence of EPS, such as dopamine D3, D4, serotonin 5-
HT2A, and α1-adrenergic receptors (Horacek, 2000). For these
reasons, the D2 equivalency method can be reductionist. In sum,
until a consistent reliable system is developed and implemented,
utilizing one dosage equivalence system versus another is likely to
introduce significant caveats in the interpretation of experimental
results, especially in the case of studies including patients treated
with clozapine or quetiapine.
The second issue that we wanted to raise concerns the fact that
most studies investigating the relationship between cognition and
EPS in schizophrenia are based on cross-sectional designs, which
are more vulnerable to confounding factors than longitudinal
designs. As rightly mentioned by Drs Salem and Moustafa, we
sought to overcome this problem in our study by performing
hierarchical multivariate linear regression analyses incorporat-
ing several socio-demographic and psychiatric variables likely to
influence the cognition–EPS association (Potvin et al., 2015). Still,
we feel that longitudinal studies are required in order to clarify the
temporal dynamics of the association we observed between cog-
nition (e.g., working memory) and drug-induced Parkinsonism.
Interestingly, several RCTs have examined the effects of antipsy-
chotics on cognition, which provide an opportunity to study the
cognition–EPS association in a longitudinal fashion. The study of
the cognition–EPS association is particularly relevant in this con-
text, since it is theoretically possible that the presumed beneficial
effects of second-generation antipsychotics (SGAs) on cognition
are actually explained by the lower liability of these drugs to induce
EPS, compared to first-generation antipsychotics (Leucht et al.,
2013). It must also be considered that by causing fewer EPS, the
treatment with SGAs renders the prescription of adjuvant anti-
cholinergic drugs less necessary, the latter being well-known to
impair cognition (Bubser et al., 2012). Recent meta-analyses have
shown that the beneficial effects of SGAs (risperidone and olan-
zapine) on cognition are small-to-moderate (Desamericq et al.,
2014). These benefits may not only reflect true effects but also be
confounded by the effects of EPS and/or anticholinergics. There-
fore, we reviewed 35 RCTs included in a recent meta-analysis
from Nielsen et al. (2015) on the effects of antipsychotic on
cognition in schizophrenia and systematically retrieved informa-
tion on anticholinergics, EPS scales, EPS–cognition associations,
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and cognitive tests (see Table 1). Of the 35 RCTs reviewed,
12 studies did not measure EPS. Of the remaining 23 studies,
only 14 performed statistics on potential associations between
EPS and cognition. Of these, six trials found an association
between EPS and cognition, and eight did not. Although such
results do not firmly establish a relationship between EPS and
cognition, they do not rule it out either, especially since the
mean duration of trials was 24weeks, which may not be long
enough to detect associations between EPS and cognition in
schizophrenia. To our knowledge, the most reliable associations
highlighted in cross-sectional studies are between cognition and
tardive dyskinesia (Pantelis et al., 2001; Wu et al., 2013), which
typically occurs later during treatment than akathisia, dysto-
nia, and parkinsonism. Also of methodological concern, among
the 35 RCTs reviewed, only 2 studies excluded anticholinergic
drugs (Note: 8 trials did not report information on anticholin-
ergics). Moreover, of the 25 remaining trials, only 9 studies
examined potential associations between changes in cognitive
performance and the prescription of adjuvant anticholinergics.
At a time when the pharmacological treatment of cognitive
deficits in schizophrenia is recognized as a top clinical priority,
the lack of knowledge on the above-mentioned factors impedes
our ability to reach valid conclusions on the presumed supe-
rior efficacy of SGAs (mostly risperidone and olanzapine) on
cognition in schizophrenia. In return, these limitations under-
mine the ongoing debate about the pharmacological mechanisms
that should be targeted to improve cognitive performance in
schizophrenia.
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